首页> 外文期刊>Cancer Biomarkers >Development and progression of colorectal neoplasia
【24h】

Development and progression of colorectal neoplasia

机译:大肠肿瘤的发展和进展

获取原文
获取原文并翻译 | 示例
           

摘要

A variety of genetic and molecular alterations underlie the development and progression of colorectal neoplasia (CRN). Most of these cancers arise sporadically due to multiple somatic mutations and genetic instability. Genetic instability includes chromosomal instability (CIN) and microsatellite instability (MSI), which is observed in most hereditary non-polyposis colon cancers (HNPCCs) and accounts for a small proportion of sporadic CRN. Although many biomarkers have been used in the diagnosis and prediction of the clinical outcomes of CRNs, no single marker has established value. New markers and genes associated with the development and progression of CRNs are being discovered at an accelerated rate. CRN is a heterogeneous disease, especially with respect to the anatomic location of the tumor, race/ethnicity differences, and genetic and dietary interactions that influence its development and progression and act as confounders. Hence, efforts related to biomarker discovery should focus on identification of individual differences based on tumor stage, tumor anatomic location, and race/ethnicity; on the discovery of molecules (genes, mRNA transcripts, and proteins) relevant to these differences; and on development of therapeutic approaches to target these molecules in developing personalized medicine. Such strategies have the potential of reducing the personal and socio-economic burden of CRNs. Here, we systematically review molecular and other pathologic features as they relate to the development, early detection, diagnosis, prognosis, progression, and prevention of CRNs, especially colorectal cancers (CRCs).
机译:各种遗传和分子改变是结直肠瘤形成(CRN)的发展和进程的基础。这些癌症大多数是由于多种体细胞突变和遗传不稳定而偶尔出现的。遗传不稳定性包括染色体不稳定性(CIN)和微卫星不稳定性(MSI),这在大多数遗传性非息肉性结肠癌(HNPCC)中观察到,占散发性CRN的一小部分。尽管许多生物标志物已用于诊断和预测CRNs的临床结局,但尚无单一标志物具有确定的价值。与CRNs的发展和进程相关的新标记和基因正在以更快的速度被发现。 CRN是一种异质性疾病,尤其是在肿瘤的解剖部位,种族/种族差异以及影响其发展和进程并充当混杂因素的遗传和饮食相互作用方面。因此,与生物标志物发现有关的工作应集中在根据肿瘤分期,肿瘤解剖位置和种族/种族识别个体差异。发现与这些差异相关的分子(基因,mRNA转录本和蛋白质);开发针对这些分子的治疗方法以开发个性化医学。此类策略具有减轻CRN的个人和社会经济负担的潜力。在这里,我们系统地回顾了分子和其他病理特征,因为它们与CRN(尤其是结直肠癌(CRC))的发展,早期发现,诊断,预后,进展和预防有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号